Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May 25, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that Company management will present a corporate overview at the Jefferies Virtual...
Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress
April 27, 2021 09:00 ET
|
Cyclerion Therapeutics, Inc.
Provided updates on development strategy and execution for CY6463, a first-in-class, CNS-penetrant sGC stimulator, including IND clearance from FDA in ADv and...
Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors
April 26, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference
April 21, 2021 07:30 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Cyclerion Therapeutics to Host Pipeline Update Webinar
April 20, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Company to discuss clinical updates for CY6463, including Phase 2a studies in ADv and MELAS, and plans to initiate Phase 1b clinical trial in CIAS Neuropsychiatric key opinion leader, Andreas Reif,...
Cyclerion Therapeutics Reports Full Year 2020 Financial Results and Corporate Update
February 25, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Novel mechanism of CY6463 demonstrated desired blood brain barrier penetration, target engagement, favorable safety and tolerability profile as well as evidence in multiple independent biomarkers...
Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards
January 25, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates CAMBRIDGE, Mass., Jan. 25, 2021 ...
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference
January 04, 2021 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious...
Cyclerion Announces Leadership Transitions
December 21, 2020 07:30 ET
|
Cyclerion Therapeutics, Inc.
Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor Cheryl Gault promoted to Chief Operating Officer Amy Schulman stepping down from Board of Directors ...
Cyclerion Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Updates
November 05, 2020 07:00 ET
|
Cyclerion Therapeutics, Inc.
Positive IW-6463 translational pharmacology study in healthy elderly subjects showed significant improvements in multiple measures associated with age-related cognitive decline and neurodegenerative...